Immune-checkpoint inhibitors (ICIs) suchas antibodies targeting CTLA-4 (ipilimumab), PDL1 (atezolizumab anddurvalumab), or PD1 (pembrolizumab and nivolumab) have become someof the most widely used anticancer therapies.47,48 However, immune-related adverse events (irAEs), such as autoimmunesymptoms and tumor hyperprogression, present a significant challengein the clinic49 and a need for the continuousdevelopment of immune-oncology pipeline drugs. Here, CTLA4 is linked to neoplasm.